Your browser doesn't support javascript.
loading
Natural history of monoclonal B-cell lymphocytosis among relatives in CLL families.
Slager, Susan L; Lanasa, Mark C; Marti, Gerald E; Achenbach, Sara J; Camp, Nicola J; Abbasi, Fatima; Kay, Neil E; Vachon, Celine M; Cerhan, James R; Johnston, James B; Call, Timothy G; Rabe, Kari G; Kleinstern, Geffen; Boddicker, Nicholas J; Norman, Aaron D; Parikh, Sameer A; Leis, Jose F; Banerji, Versha; Brander, Danielle M; Glenn, Martha; Ferrajoli, Alessandra; Curtin, Karen; Braggio, Esteban; Shanafelt, Tait D; McMaster, Mary L; Weinberg, J Brice; Hanson, Curtis A; Caporaso, Neil E.
Afiliação
  • Slager SL; Department of Health Sciences Research, Mayo Clinic, Rochester, MN.
  • Lanasa MC; Department of Medicine, Duke University, Duke Cancer Institute, Durham, NC.
  • Marti GE; Lymphoid Malignancies Section, Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD.
  • Achenbach SJ; Department of Health Sciences Research, Mayo Clinic, Rochester, MN.
  • Camp NJ; Department of Internal Medicine, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT.
  • Abbasi F; Center for Biologics Research and Evaluation, Food and Drug Administration, Silver Springs, MD.
  • Kay NE; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN.
  • Vachon CM; Department of Health Sciences Research, Mayo Clinic, Rochester, MN.
  • Cerhan JR; Department of Health Sciences Research, Mayo Clinic, Rochester, MN.
  • Johnston JB; Department of Internal Medicine, Max Rady College of Medicine, University of Manitoba, Winnipeg, MB, Canada.
  • Call TG; Research Institute in Oncology and Hematology, CancerCare Manitoba, Winnipeg, MB, Canada.
  • Rabe KG; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN.
  • Kleinstern G; Department of Health Sciences Research, Mayo Clinic, Rochester, MN.
  • Boddicker NJ; Department of Health Sciences Research, Mayo Clinic, Rochester, MN.
  • Norman AD; Department of Health Sciences Research, Mayo Clinic, Rochester, MN.
  • Parikh SA; Department of Health Sciences Research, Mayo Clinic, Rochester, MN.
  • Leis JF; Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, MN.
  • Banerji V; Department of Hematology and Oncology, Mayo Clinic, Phoenix, AZ.
  • Brander DM; Department of Internal Medicine, Max Rady College of Medicine, University of Manitoba, Winnipeg, MB, Canada.
  • Glenn M; Research Institute in Oncology and Hematology, CancerCare Manitoba, Winnipeg, MB, Canada.
  • Ferrajoli A; Department of Biochemistry and Medical Genetics, Max Rady College of Medicine, University of Manitoba, Winnipeg, MB, Canada.
  • Curtin K; Department of Medicine, Duke University, Duke Cancer Institute, Durham, NC.
  • Braggio E; Department of Internal Medicine, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT.
  • Shanafelt TD; Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX.
  • McMaster ML; Department of Internal Medicine, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT.
  • Weinberg JB; Department of Hematology and Oncology, Mayo Clinic, Phoenix, AZ.
  • Hanson CA; Division of Hematology, Department of Medicine, Stanford University School of Medicine, Palo Alto, CA.
  • Caporaso NE; Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Blood ; 137(15): 2046-2056, 2021 04 15.
Article em En | MEDLINE | ID: mdl-33512457
ABSTRACT
Chronic lymphocytic lymphoma (CLL) has one of the highest familial risks among cancers. Monoclonal B-cell lymphocytosis (MBL), the precursor to CLL, has a higher prevalence (13%-18%) in families with 2 or more members with CLL compared with the general population (5%-12%). Although, the rate of progression to CLL for high-count MBLs (clonal B-cell count ≥500/µL) is ∼1% to 5%/y, no low-count MBLs have been reported to progress to date. We report the incidence and natural history of MBL in relatives from CLL families. In 310 CLL families, we screened 1045 relatives for MBL using highly sensitive flow cytometry and prospectively followed 449 of them. MBL incidence was directly age- and sex-adjusted to the 2010 US population. CLL cumulative incidence was estimated using Kaplan-Meier survival curves. At baseline, the prevalence of MBL was 22% (235/1045 relatives). After a median follow-up of 8.1 years among 449 relatives, 12 individuals progressed to CLL with a 5-year cumulative incidence of 1.8%. When considering just the 139 relatives with low-count MBL, the 5-year cumulative incidence increased to 5.7%. Finally, 264 had no MBL at baseline, of whom 60 individuals subsequently developed MBL (2 high-count and 58 low-count MBLs) with an age- and sex-adjusted incidence of 3.5% after a median of 6 years of follow-up. In a screening cohort of relatives from CLL families, we reported progression from normal-count to low-count MBL to high-count MBL to CLL, demonstrating that low-count MBL precedes progression to CLL. We estimated a 1.1% annual rate of progression from low-count MBL, which is in excess of that in the general population.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfócitos B / Leucemia Linfocítica Crônica de Células B / Linfocitose Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Linfócitos B / Leucemia Linfocítica Crônica de Células B / Linfocitose Idioma: En Ano de publicação: 2021 Tipo de documento: Article